{"name":"SUN PHARM INDS","slug":"sun-pharm-inds","ticker":"","exchange":"","domain":"sunpharminds.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2600000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Leqselvi","genericName":"DEURUXOLITINIB","slug":"deuruxolitinib","revenue":2600000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2024-01-01","label":"Leqselvi first approved","drug":"Leqselvi","drugSlug":"deuruxolitinib","type":"approval","sentiment":"positive"},{"date":"2024-01-01","label":"Octreoscan first approved","drug":"Octreoscan","drugSlug":"pentetreotide","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":2600000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Leqselvi","genericName":"DEURUXOLITINIB","slug":"deuruxolitinib","indication":"severe alopecia areata","status":"marketed","revenue":2600000000}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Octreoscan","genericName":"PENTETREOTIDE","slug":"pentetreotide","indication":"primary neuroendocrine tumors","status":"marketed"}]}],"pipeline":[{"name":"Leqselvi","genericName":"DEURUXOLITINIB","slug":"deuruxolitinib","phase":"marketed","mechanism":"Deuruxolitinib inhibits JAK1, JAK2, and TYK2, modulating cytokine and growth factor signaling involved in hematopoiesis and immune function.","indications":["severe alopecia areata"],"catalyst":""},{"name":"Octreoscan","genericName":"PENTETREOTIDE","slug":"pentetreotide","phase":"marketed","mechanism":"Recombinant protein","indications":["primary neuroendocrine tumors","metastatic neuroendocrine tumors"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":9,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}